Dimethyl fumarate for the treatment of multiple sclerosis

Details Dimethyl fumarate for the treatment of multiple sclerosis Dimethyl fumarate for the treatment of multiple sclerosis

2002-07-17

2008-01-22

Henley, III, Raymond J. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

Reexamination Certificate

active

07320999

ABSTRACT:
The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

REFERENCES:
patent: 3832287 (1974-08-01), Gale et al.
patent: 4515974 (1985-05-01), Zecher et al.
patent: 4746668 (1988-05-01), Sato et al.
patent: 4851439 (1989-07-01), Speiser et al.
patent: 4959389 (1990-09-01), Speiser et al.
patent: 5149695 (1992-09-01), Speiser et al.
patent: 5214196 (1993-05-01), Blank
patent: 5242905 (1993-09-01), Blank
patent: 5359128 (1994-10-01), Blank
patent: 5424332 (1995-06-01), Speiser et al.
patent: 5451667 (1995-09-01), Speiser et al.
patent: 5538968 (1996-07-01), Chiesi et al.
patent: 5548059 (1996-08-01), Bayley et al.
patent: 5589504 (1996-12-01), Dannenberg et al.
patent: 5972363 (1999-10-01), Clikeman et al.
patent: 6277882 (2001-08-01), Joshi et al.
patent: 6355676 (2002-03-01), Joshi et al.
patent: 6359003 (2002-03-01), Joshi et al.
patent: 6436992 (2002-08-01), Joshi et al.
patent: 6509376 (2003-01-01), Joshi et al.
patent: 2003/0013761 (2003-01-01), Joshi et al.
patent: 2006/0069161 (2006-03-01), Lee et al.
patent: 2248955 (2001-08-01), None
patent: 1125141 (1996-06-01), None
patent: 25 30 372 (1977-01-01), None
patent: 26 21 214 (1977-11-01), None
patent: 35 31 597 (1987-03-01), None
patent: 38 34794 (1990-04-01), None
patent: 3834794 (1990-04-01), None
patent: 0 188 749 (1986-07-01), None
patent: 0 312 697 (1989-04-01), None
patent: 0 312 697 (1989-04-01), None
patent: 0 518 388 (1992-12-01), None
patent: 0 793 966 (1997-09-01), None
patent: 1 216 699 (1970-12-01), None
patent: 1 422 726 (1976-01-01), None
patent: 2 291 422 (1996-01-01), None
patent: WO 89/01930 (1989-03-01), None
patent: WO 94/28883 (1994-12-01), None
patent: WO 95/25102 (1995-09-01), None
patent: WO 96/01122 (1996-01-01), None
patent: WO 96/02244 (1996-02-01), None
patent: WO 96/27369 (1996-09-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 98/04290 (1998-02-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 98/52549 (1998-11-01), None
patent: WO 99/21565 (1999-05-01), None
patent: WO 01/59072 (2001-08-01), None
patent: WO 02/02190 (2002-01-01), None
patent: WO 03/032969 (2003-04-01), None
patent: WO 2004/096216 (2004-11-01), None
patent: WO 2005/027899 (2005-03-01), None
patent: WO 2005/044272 (2005-05-01), None
patent: WO 2006/037342 (2006-04-01), None
patent: WO 2006/050730 (2006-05-01), None
patent: WO 2006/055871 (2006-05-01), None
Anderson, A. et al., Contact Dermatitis, 16:55-78, 1987.
deJong et al., European Journal of Immunology, 26:2067-2074, 1996.
Dücker, P. et al., H+Z Zeitschrift fur Haut., 65:734-736, 1989.
Fliegner, L. et al., Hautarzt, 43:554-560, 1992.
Ghoreschi et al., Arch. Dermatol. Res., 296:P110, 2005.
Ghoreschi et al., Arch. Dermatol. Res., 294:28, 2002.
Ghoreschi et al., Current Drug Targets: Inflammation and Allergy 3:193-198, 2004.
Hunziker et al., “Is Psoriasis an Autoimmune Disease?”, excerpt from “Therapeutische Umschau”, Derm. Clinic of Univ. Berne, 50:110-113, 1993, translated version 5 pages.
International Search Report for PCT/EP99/08215 dated Jun. 26, 2000.
Kiehl, R et al., Acta Derm. Venerol., 72:253-255, 1992.
Kolbach, D. et al., J. Am. Acad. Derm., 27:769-771, 1992.
Lahti, A. et al., Contact Dermatitis, 12:139-140, 1985.
Merck Index, 10th Ed., 1983 Abs. 2748.
Nieboer, C. et al., J. Am. Acad. Derm., 20:601-608, 1989.
Peeters et al., Br. J. Rheumatol., 317:502-504, 1992.
Peeters et al., Ned. Tijdschr. Geneeskd., 136:2428-2431, 1992.
Sadjak, A. et al., Deutsch Med. Wochenschr., 116:478, 1991.
Schilling et al., Clinical and Experimental Immunology, 145:101-107, 2006.
Schilling et al., Aktuelle Rheumatologie, 24(6):174-179, 1999.
Schimrigk et al., European J. of Neurology: The Official Journal of the European Federation of Neurological Societies, 13:604-610, 2006.
Sebok, B. et al., Skin Pharm., 9:99-103, 1996.
Thio, H. et al., Br. J. Dermatol., 131:865-861, 1994.
English Language Derwent Abstract for CN 1125141, date unavailable.
English Language Derwent Abstract for DE 35 31 597, date unavailable.
Altmeyer, P. et al., “Systemische Therapie der Psoriasis”, T & E Dermatologie Jg., 1997, vol. 27, pp. 380-382, 384—not translated.
M. Bacharach-Buhles et al., “Fumaric Acid Esters (FAEs) Suppress CD 15- and ODP 4-positive Cells in Psoriasis”, Acta Derm Venerol (Stockh); 1994; Suppl. 186: 79-82.
H. M. Ockenfels, et al., “The antipsoricatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network”, British Journal of Dermatology, 1998, vol. 139, 390-395.
Gasser, et al., “Host Vs Graft and Graft Vs Host Reactions After Allogenic Heterotopic Small Bowel Transplantation in the Rat”, Transplantation Proceedings, vol. 24, No. 3, Jun. 1992, pp. 1128-1129.
Hunziker T. et al.; “Is Psoriasis an Autoimmune Disease”, Excerpt from “Therapeutische Umschau”, Determatological Clinic of the University of Berne; 1993, vol. 50; 2ndedition; pp. 110-113. (Translated version 5 pages).
Nathens, et al., “The Glutathione Depleting Agent Diethylmaleate Prolongs Renal Allograft Survival”, Journal of Surgical Research, vol. 77, 1998, pp. 75-79.
Nibbering, P.H. et al., “Intracellular Signalling by Binding Sites for the Antipsoratic Agent Monomethylfumarate on Human Granulocytes”, British J. Dermatol., 1997, vol. 137, pp. 65-75.
Nibbering, Peter H., “Effects of Monomethylfumarate on Human Granulocytes”, Journal of Investigative Dermatology, 1993, vol. 101, pp. 37-42.
Sebök, Bela et al., “Antiproliferative and Cytotoxic profiles of Antipsoriatic Fumaric Acid Derivatives in Keratinocyte Cultures”, European Journal of Pharm., Environ. Toxicol. Pharmacol. Sect., 1994, vol. 270, pp. 79-87.
Schwinghammer et al., “Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation”, Therapy Reviews, Clinical Pharmacy, vol. 12, Oct. 1993, pp. 736-761.
Medline Abstract of Bayard et al., “Peroral long-term treatment of psoriasis using fumaric acid derivatives”, Hautarzt, May 1987, 38(5), pp. 279-85.
“Merck Manual”, 1987, Merck XP-002141006, p. 327, paragraph 2-paragraph 6.
Immunmodulation durch Fumaderm, Das richtungsweisende Konzept, Charité-Berlin, Hautklinik, Symposium, 1.-3. Nov. 1996, 28 pages, 4 page english translation of pp. 23-24.
Amamoto, Toshiro, et al., “Effect of E-64, Thiol Protease Inhibitor on the Secondary Anti-SRBC Response In Vitro”, Microbiol. Immunol., vol. 28(1), 1984, pp. 85-97.
Barrett, Alan J., et al., “L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L”, Biochem. J., 1982, vol. 201, pp. 189-198.
Bellier, Bruno, et al., “Replacement of Glycine with Dicarbonyl and Related Moieties in Analogues of the C-Terminal Pentapeptide of Cholecystokinin: CCK2Agonists Displaying a Novel Binding Mode”, J. Med. Chem., vol. 43, 2000, pp. 3614-3623.
Birch, A.J., et al., “Metabolites ofAspergillus indicus: The Structure and Some Aspects of the Biosynthesis of Dihydrocanadensolide”, Aust. J. Chem., 1968, vol. 21, pp. 2775-2784.
Choo, Hea-Young, et al., “Design and Synthesis of α,β-unsaturated Carbonyl Compounds as Potential ACE Inhibitors”, Short Communication, Eur. J. Med. Chem., vol. 35, 2000, pp. 643-648.
Dethlefsen, L.A., “Toxic Effects of Acute Glutathione Depletion by Buthionine Sulfoximine and Dimethylfumarate on Murine Mammary Carcinoma Cells”, Radiation Research, vol. 114, 1988,

Affiliated with

Also associated with

Rating

Dimethyl fumarate for the treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dimethyl fumarate for the treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dimethyl fumarate for the treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3964552